Japanese drugmaker Shionogi's Covid-19 pill Xocova, also known as S-217622. - Reuters
TOKYO (Bloomberg): Shionogi & Co’s experimental Covid-19 treatment Xocova failed to win the backing of health experts in Japan who said there wasn’t enough data to show the medicine’s efficacy.
The panel members didn’t recommend that Japan’s health ministry authorise emergency use of the therapy and said there was a need to continue discussion on it, Hiroshi Kiyota, chairman of the expert committee in a briefing on Wednesday.
Already a subscriber? Log in.
Get 30% off with our ads free Premium Plan!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
